Equinox Gold management commentary attributes Q3 2026 net income decline to higher taxes
Bitget2026/11/09 22:16- Equinox Gold management commentary reported Q3 2026 net income of USD 62.5 million, down from USD 75.6 million a year earlier.
- Management attributed the decline primarily to higher Canadian income taxes and lower earnings from discontinued Brazilian operations, partly offset by stronger mining income.
- Revenue from continuing operations rose 79% to USD 1.05 billion, driven by higher realized gold prices and increased sales volumes.
- Mining income benefited from acquired operations, Valentine's commercial production and Greenstone's continued ramp-up, according to management.
- Nine-month net income reached USD 603.2 million versus USD 24 million, primarily reflecting stronger mining income and lower finance expense.
Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.
You may also like
BUZZ - Rocket Lab’s stock falls as quarterly loss exceeds expectations
BUZZ-Take-Two shares rise after raising annual revenue and profit forecasts
Itaúsa Q3 2026 recurring net profit rises 25% to R$ 5.06 billion year-on-year
The US FDA requires semaglutide, tirzepatide, and other GLP-1 drugs to include new warnings about the risk of eye disease.
NAION is an eye disease that can cause sudden, painless loss of vision, with some patients potentially experiencing permanent visual impairment. The drugs involved include products from Eli Lilly and Novo Nordisk. According to analysts at Citi, the incidence of NAION is relatively low, and given the significant benefits of GLP-1 drugs in weight control and blood sugar management, the actual impact on prescription behavior is expected to be limited. On Monday, the stock prices of Eli Lilly and Novo Nordisk increased, with the news not causing any significant impact on their share prices.
Crypto prices
More
